Introduction
Pseudomonas aeruginosa is an aerobic, motile, gram negative rod that belongs to the family, Pseudomonadaceae. 1 They are often multidrug resistant due to intrinsic and acquired determinants. 2 It can survive with low levels of nutrients and grow in temperatures ranging from 4 to 42°C. 3, 4 It can cause urinary tract infections, respiratory infections, dermatitis, soft tissue infections, bacteremia, bone and joint infections and gastrointestinal infections. It is responsible for a variety of systemic infections, particularly in patients with severe burns, and bed sore. 5, 6 P. aeruginosa also causes severe infections in patients with diseases including cancer, diabetes, cystic fibrosis, immune-suppression, and major surgery. 7 The bacteria can colonize implanted devices, catheters, heart valves, ventilators or dental implants resulting in deviceassociated hospital acquired infections which are of major concern globally. 8 The resistance rates of P. aeruginosa are increasing globally creating a serious public health threat.
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P. aeruginosa is characterized by increased resistance to antipseudomonal agents. 10 In vitro sensitivity tests are used as a guide for appropriate antimicrobial therapy prior to antibiotic treatments. Globally, the differences in the resistance rates of P. aeruginosa usually correlate with the prescription patterns of antibiotics by physicians, overuse of antibiotics, and the selective pressure of certain antibiotics. 11 Recent, studies showed that susceptibility of P. aeruginosa to currently used anti-pseudomonal agents, including ß-lactams, aminoglycosides, and fluoro-quinolones is decreasing. 12 Since resistance of P. aeruginosa to carbapenems, piperacillin, and other highly active antibiotics has emerged and is increasing, it makes treatment of P. aeruginosa infections troublesome. 10 The current study further examined the susceptibilities and resistances of P. aeruginosa to anti-pseudomonal drugs, isolated from various clinical specimens. 
Materials & Methods

Antimicrobial susceptibility
Antimicrobial susceptibility was performed on MuellerHinton agar by standard disc diffusion method recommended by Clinical and Laboratory Standards Institute (CLSI). 13 This was done by soaking a sterile swab in MacFarlands solution and then carefully swabbing the entire surface of MuellerHinton agar plates. The antibiotic discs were placed on the surface of the inoculated plates and gently pressed. The antibiotics used against the P. aeruginosa were as follows: amikacin (30µg), cefepime (30µg), cefotaxime (30µg), ceftazidime (30µg), cefuroxime (30µg) ceftriaxone (30µg), cotrimoxazole (25µg), ciprofloxacin (5µg), imipenem (10µg), meropenem (10µg), and gentamicin (10µg). The plates were incubated at 37°C for 18-24 hours. The diameter of inhibition zone was measured in millimeters and isolates were scored as sensitive or resistant by comparing with values recommended on standard.
13
Results
Out of 4489 various clinical samples 138 P. aeruginosa were isolated. The rate of isolation of P. aeruginosa was 3.07%. Of these 138 isolates of P. aeruginosa, 75.36% were from males and 24.64% were from females (Table I) . Among the positive isolates, 89 (64.49%) were from wound sample, which were the predominant source of specimens of P. aeruginosa, and followed by pus 18 (13.04%), urine 17 (12.31%). Isolates from sputum, ear swab, throat swab and catheter tips were very small quantity (Table II) . In this study, P. aeruginosa showed high resistance to cotrimoxazole and cefuroxime 91 to 96%. Resistance rates to cefepime, ceftriaxone, cefotaxime, and gentamicin varied from 47% to 88%. All the isolates were comparatively better susceptible to meropenem, ciprofloxacin, amikacin and imipenem which range from 76 to 87%. another study. In this study, the commonest sample was wound swab 64.49%, followed by pus 13.04%, urine 12.31% and sputum 7.97%. The distribution of specimens of P. aeruginosa may vary with each hospital as each hospital facility has a different environment associated with it. About 90% of the P. aeruginosa isolates of this study were obtained from only three important specimens e.g. wound swab, pus, and urine. Similar results had been obtained in India reported by Andhale et. al., 16 and Pathi et. al., 19 in different studies.
In our study, percentage of P. aeruginosa isolated was 3.07% which was close to the result reported in a study as 3.27%. 20 In Nepal, P. aeruginosa accounted for 1.20% of the total cultures. 21 Study from Palestine showed prevalence of P.
aeruginosa to be 9%. 22 According to our study, P. aeruginosa can be best treated with imipenem with minimum resistance (13.24%), followed by amikacin (16.06%). Similar kind of results was seen in studies from countries like India, 16, 20, 23 Nepal, 19 Pakistan 24 and Poland 25 where highest sensitivity was observed against imipenem followed by amikacin. But the sensitivity in Poland showed almost 100%, where for South East Asian region it was < 90% and lower sensitivity seen in a study done in Iran 26 which is ranged from 55-57%. Sensitivity of gentamicin in this study was found 53.3% against P. aeruginosa while similar observation were found in two studies from India 23 A study from Pakistan in 2015 also found similar kind of result about cephalosporin's sensitivity where cefotaxime was found most effective against P. aeruginosa with 54.5% sensitivity, followed by ceftazidime (43.9%), ceftriaxone (38.3%) and cefepime (36.1%). 24 P. aeruginosa strains in this study exhibited a high rate of resistance to the third generation cephalosporin drug-ceftriaxone (63.5%). A much higher resistance to ceftriaxone of 75%, 86% and 93.9% had been reported in studies done in India 28 , Bangladesh 29 and Nepal. 30 Lower rate of resistance to ceftriaxone (40%) had been reported in another study from Andhra Pradesh, India.
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Another cephalosporin drug-cefepime showed higher resistance rate of 80.43% in this study. But low resistance observed from studies from Pakistan, 24 India, 23 and Iran. 26 A study from Palestine, 22 showed resistance of ceftazidime to be 13.3% and that of Cefuroxime to be 53.3% while in our study it was 68.84% and 96.27%, respectively. In contrast, resistance level of ceftazidime and ceftriaxone found by Paryani et. al., 20 were 3% and 13% respectively, which differs greatly with our study. It does indicate the relative efficacy of these drugs amongst the cephalosporins against P. aeruginosa. The rate of resistance for the anti-folate drug co-trimoxazole in the present study was 91.24%. Similarly, a previous study in Bangladesh 32 showed rate of resistance for co-trimoxazole to be 92% in ICU patients while studies from Nigeria 33 showed ciprofloxacin 70.3% sensitive among P. aeruginosa examined. But other studies have showed varying degrees of sensitivity in recent years which ranged from 37 to 66.6%. 16, 18, [23] [24] [25] [26] 35 Irrational and inappropriate use of antibiotics is responsible for the development of resistance of many microorganisms including Pseudomonas species to antibiotic. So, emphasize should be given to the rational use of antimicrobials. Some drugs should kept reserve to minimize the misuse of available antimicrobials. In addition, regular antimicrobial susceptibility surveillance is essential for monitoring of the antibiogram patterns for better patient management.
Conclusion
P. aeruginosa is one of the most frequently isolated pathogen from the clinical specimens. In this study, imipenem, and amikacin proved to be the most sensitive drug against P. aeruginosa. Variation in sensitivity among these drugs in different studies poses importance of keeping those drugs as reserve drugs. This study found that ciprofloxacin can be used for routine treatment against P. aeruginosa. Use of cephalosporins and cotrimoxazole should be restricted as it found to be least effective against P. aeruginosa.
